Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock’s 30-day volume-weighted average price, and the financing is expected to close on ...

Adverum Biotechnologies, Inc. (ADVM) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Adverum Biotechnologies, Inc. ADVM announced that it has completed the investigational new drug (“IND”) amendment with the FDA to begin a mid-stage study on its gene therapy candidate, ADVM-022, for ...

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even ...

Adverum Biotechnologies ADVM dosed first subject in the LUNA Phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular ...

We can judge whether Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's ...

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are ...

Adverum Biotechnologies, Inc. ADVM announced that it has received feedback from the FDA on its investigational new drug (IND) application for initiating a phase II study to evaluate its eye disorder ...